Endpoints NewsOriginal article
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
Phase 3positiveDysportPositive
AI Analysis
Summary
Ipsen's Dysport met the primary endpoint in Phase 3 migraine trials by reducing monthly migraine days. Separately, Tarsus acquired iRenix for $75 million upfront.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Met primary endpoint of reducing monthly migraine days
Importance:7/10
Sentiment:
0.85
Phase 3 successmigraineDysportIpsenM&Aneurotoxin
Related Companies
Read the original article
Published by Endpoints News on July 9, 2026 2:36 PM